The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial
- 9 May 2022
- journal article
- research article
- Published by Wiley in Depression and Anxiety
- Vol. 39 (5) , 429-440
Abstract
Improving treatment outcomes for smokers with Major Depressive Disorder (MDD) can have significant public health implications. To evaluate the safety and efficacy of smoking cessation pharmacotherapy among smokers with MDD. Secondary analysis of a randomized, double-blind, active- (nicotine patch) and placebo-controlled trial of 12 weeks of either varenicline or bupropion with 12-week follow-up. Community volunteers 18-75 years of age; smoke 10+ cigarettes/day; with clinically stable MDD(N=2635) or no psychiatric disorder(N=4028), from 140 sites in 16 countries. 12 weeks of pharmacotherapy (placebo, PLA; nicotine replacement therapy, NRT; bupropion, BUP; varenicline, VAR) plus brief cessation counseling. Primary safety outcome: the occurrence of ≥ 1 treatment-emergent, moderate to severe Neuropsychiatric Adverse Event (NPSAE). Primary efficacy outcome: biochemically confirmed continuous abstinence (CA) during the final 4 weeks of treatment (Weeks 9–12). 6,653 participants (56% female; 39% MDD) ~47 years old. Risk of NPSAEs did not differ by medication for MDD. MDD had higher risk (p<0.0001) for NPSAEs than the non-psychiatric cohort (NPC). Efficacy (6,653; intent-to-treat): CA rates for MDD vs. NPC respectively were 31.2% vs. 38.0% VAR; 23.0% vs 26.1% BUP; 22.6% vs 26.4% NRT; and 13.4% vs. 13.7% PLA but no differential treatment effect was noted within the cohorts. All active treatments differed from PLA but VAR showed the largest effect. Results suggest that for MDD smokers, inclusive of those with recurrent episodes (RE), varenicline plus counseling may be the best pharmacological option for the treatment of smoking given its greater efficacy effect size and similar risk of NPSAEs. ClinicalTrials.gov Identifier: NCT01456936. https://clinicaltrials.gov/ct2/show/NCT01456936Keywords
Funding Information
- GlaxoSmithKline (NCT01456936)
- Pfizer (NCT01456936)
This publication has 36 references indexed in Scilit:
- Predictors of persistent nicotine dependence among adults in the United StatesDrug and Alcohol Dependence, 2011
- Current Major Depression Among Smokers Using a State QuitlineAmerican Journal of Preventive Medicine, 2011
- Nicotine withdrawal in U.S. smokers with current mood, anxiety, alcohol use, and substance use disordersDrug and Alcohol Dependence, 2010
- Psychiatric disorders in smokers seeking treatment for tobacco dependence: Relations with tobacco dependence and cessation.Journal of Consulting and Clinical Psychology, 2010
- Single versus recurrent depression history: Differentiating risk factors among current US smokersDrug and Alcohol Dependence, 2010
- Gender Differences in Associations between Lifetime Alcohol, Depression, Panic Disorder, and Posttraumatic Stress Disorder and Tobacco WithdrawalThe American Journal on Addictions, 2009
- A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults With Unipolar Depressive DisordersJournal of Clinical Psychopharmacology, 2008
- Twelve-Month Use of Mental Health Services in the United StatesArchives of General Psychiatry, 2005
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983